JAK2 V617F Mutation Analysis

Clinical Significance

This DNA-based assay tests leukocytes from blood or bone marrow aspirate for mutation at codon 617 of JAK2, using an advanced DNA sequencing method. The JAK2 V617F mutation is associated with myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis

Specimen Requirements

5.0 mL Whole Blood in a Lavender Top Tube - EDTA

Transport And Storage

7 days Ambient
7 days Refrigerated

Collection Instructions

 

Minimum Volume

3.0 mL Whole Blood EDTA

Neonatal Volume

Reference Range:

Refer to Interpretive Results

Methodology:

• DNA Sequencing
• Polymerase Chain Reaction (PCR)

Clinical Significance

This DNA-based assay tests leukocytes from blood or bone marrow aspirate for mutation at codon 617 of JAK2, using an advanced DNA sequencing method. The JAK2 V617F mutation is associated with myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis

CDM

00918200

CPT Coding

81479